entertainment -WSS

entertainment

author：comprehensive 2025-09-28 01:39:37 - browse：642

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Ozempic cut risk of death in diabetes patients with chronic kidney disease

explore

WSS

CDC overhauls leadership of center that led response to Covid

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

The history of OxyContin, told through Purdue Pharma documents

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Some medical students still think black patients feel less pain

focus

entertainment

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Decentralized clinical trials need collaboration to achieve wider use

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The perfect storm of weather conditions that led to the devastating wildfires in Maui

New air purifier tech could be key to improving indoor air quality

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

23andMe had bad news about my health. I wish a person had delivered it

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

Duchenne breakthrough therapy leaves behind pioneering families

Why we need mandatory labeling of GMO products

entertainment

Pharma’s losing bet in New Jersey

Unmasking the 'centricity' illusion in clinical trials

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Hospitals need to get ahead of regulations on climate change

Genentech weighs delaying cancer therapy after drug pricing law

Protect nursing home residents from future pandemics

knowledge

explore

explore

leisure time